Skip to main content
Top
Published in: Rheumatology International 9/2013

01-09-2013 | Original Article

Relation of rheumatoid factor and anti-cyclic citrullinated peptide antibody with disease activity in rheumatoid arthritis: cross-sectional study

Authors: Jung-Yoon Choe, Jisuk Bae, Hwajeong Lee, Sang-Cheol Bae, Seong-Kyu Kim

Published in: Rheumatology International | Issue 9/2013

Login to get access

Abstract

To analyze the association of rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (anti-CCP) with non-remission and with disease activity measures in rheumatoid arthritis (RA). Cross-sectional study of consecutive RA patients. Non-remission was defined as a disease activity score (DAS28) ≥2.6 at study enrollment. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI) were additionally measured. Serum titers of RF and anti-CCP were transformed into incremental levels (100/units) and log-transformed levels. Analysis of association with non-remission was done with logistic regression models, with and without adjustment for age, sex, disease duration, and corticoid use. Multiple regression models, raw and similarly adjusted, were used to measure the association of RF and anti-CCP with the disease activity measures. A total of 385 patients were included, of whom 286 (74 %) were not in remission. Log-transformed RF level was associated with an increased risk of non-remission after adjustment (OR = 1.32, 95 % CI 1.04–1.67). This association was especially evident in patients with less than 10 years of disease duration (OR = 1.51, 95 % CI 1.15–1.99) and in those using steroids (OR = 2.06, 95 % CI 1.22–3.48). Serum RF titers and log-transformed RF levels showed a small but significant association with DAS28 score (adjusted beta coefficients 0.002 and 0.18, respectively; both p ≤ 0.01), but neither with SDAI or CDAI nor with anti-CCP antibody. : Log-transformed RF levels might be associated with non-remission in RA, especially in patients with short disease duration or on steroids.
Literature
1.
go back to reference Houssien DA, Jonsson T, Daview E, Scott DL (1998) Rheumatoid factor isotypes, disease activity and the outcome of rheumatoid arthritis. Comparative effects of different antigens. Scand J Rheumatol 27:46–53PubMedCrossRef Houssien DA, Jonsson T, Daview E, Scott DL (1998) Rheumatoid factor isotypes, disease activity and the outcome of rheumatoid arthritis. Comparative effects of different antigens. Scand J Rheumatol 27:46–53PubMedCrossRef
2.
go back to reference Bukhari M, Lunt M, Harrison BJ, Scott DGI, Symmons DPM, Silman AJ (2002) Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis. Results from the Norfolk arthritis register study, a large inception cohort. Arthritis Rheum 46:906–912PubMedCrossRef Bukhari M, Lunt M, Harrison BJ, Scott DGI, Symmons DPM, Silman AJ (2002) Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis. Results from the Norfolk arthritis register study, a large inception cohort. Arthritis Rheum 46:906–912PubMedCrossRef
3.
go back to reference Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van’t Hof M et al (2000) The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 43:1831–1835PubMedCrossRef Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van’t Hof M et al (2000) The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 43:1831–1835PubMedCrossRef
4.
go back to reference Vencovský J, Machácek S, Sedová L, Kafková J, Gatterová J, Pesáková V et al (2003) Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 62:427–430PubMedCrossRef Vencovský J, Machácek S, Sedová L, Kafková J, Gatterová J, Pesáková V et al (2003) Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 62:427–430PubMedCrossRef
5.
go back to reference Manfredsdottir VF, Vikingsdottir T, Jonsson T, Geirsson AJ, Kjartansson O, Heimisdottir M (2006) The effects of tobacco smoking and rheumatoid factor seropositivity on disease activity and joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 45:734–740CrossRef Manfredsdottir VF, Vikingsdottir T, Jonsson T, Geirsson AJ, Kjartansson O, Heimisdottir M (2006) The effects of tobacco smoking and rheumatoid factor seropositivity on disease activity and joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 45:734–740CrossRef
6.
go back to reference Eberhardt KB, Truedsson L, Pettersson H, Svensson B, Stigsson L, Eberhardt JL et al (1990) Disease activity and joint damage progression in early rheumatoid arthritis: relation to IgG, IgA, and IgM rheumatoid factor. Ann Rheum Dis 49:906–909PubMedCrossRef Eberhardt KB, Truedsson L, Pettersson H, Svensson B, Stigsson L, Eberhardt JL et al (1990) Disease activity and joint damage progression in early rheumatoid arthritis: relation to IgG, IgA, and IgM rheumatoid factor. Ann Rheum Dis 49:906–909PubMedCrossRef
7.
go back to reference Ateş A, Kinikli G, Turgay M, Akay G, Tokgöz G (2007) Effects of rheumatoid factor isotypes on disease activity and severity in patients with rheumatoid arthritis: a comparative study. Clin Rheumatol 26:538–545PubMedCrossRef Ateş A, Kinikli G, Turgay M, Akay G, Tokgöz G (2007) Effects of rheumatoid factor isotypes on disease activity and severity in patients with rheumatoid arthritis: a comparative study. Clin Rheumatol 26:538–545PubMedCrossRef
8.
go back to reference del Val del Amo N, Ibanez Bosch R, Fito Manteca C, Gutierrez Polo R, Loza Cortina E (2006) Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: relation with disease aggressiveness. Clin Exp Rheumatol 24:281–286PubMed del Val del Amo N, Ibanez Bosch R, Fito Manteca C, Gutierrez Polo R, Loza Cortina E (2006) Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: relation with disease aggressiveness. Clin Exp Rheumatol 24:281–286PubMed
9.
go back to reference Miriovsky BJ, Michaud K, Thiele GM, O’Dell JR, Cannon GW, Kerr G et al (2010) Anti-CCP antibody and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritis. Ann Rheum Dis 69:1292–1297PubMedCrossRef Miriovsky BJ, Michaud K, Thiele GM, O’Dell JR, Cannon GW, Kerr G et al (2010) Anti-CCP antibody and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritis. Ann Rheum Dis 69:1292–1297PubMedCrossRef
10.
go back to reference Serdaroğlu M, Cakirbay H, Değer O, Cengiz S, Kul S (2008) The association of anti-CCP antibodies with disease activity in rheumatoid arthritis. Rheumatol Int 28:965–970PubMedCrossRef Serdaroğlu M, Cakirbay H, Değer O, Cengiz S, Kul S (2008) The association of anti-CCP antibodies with disease activity in rheumatoid arthritis. Rheumatol Int 28:965–970PubMedCrossRef
11.
go back to reference Prevoo MLL, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM (1995) Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMedCrossRef Prevoo MLL, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM (1995) Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMedCrossRef
12.
go back to reference Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G et al (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 42:244–257CrossRef Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G et al (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 42:244–257CrossRef
13.
go back to reference Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K et al (2005) Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 7:R796–R806PubMedCrossRef Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K et al (2005) Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 7:R796–R806PubMedCrossRef
14.
go back to reference Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef
15.
go back to reference De Rycke L, Verhelst X, Kruithof E, Van den Bosch F, Hoffman IE, Veys EM et al (2005) Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis 64:299–302PubMedCrossRef De Rycke L, Verhelst X, Kruithof E, Van den Bosch F, Hoffman IE, Veys EM et al (2005) Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis 64:299–302PubMedCrossRef
16.
go back to reference Alarcon GS, Schrohenloher RE, Bartolucci AA, Ward JR, Williams HJ, Koopman WJ (1990) Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis. Evidence for differential influences of therapy and clinical status on IgM and IgA rheumatoid factor expression. Arthritis Rheum 33:1156–1161PubMedCrossRef Alarcon GS, Schrohenloher RE, Bartolucci AA, Ward JR, Williams HJ, Koopman WJ (1990) Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis. Evidence for differential influences of therapy and clinical status on IgM and IgA rheumatoid factor expression. Arthritis Rheum 33:1156–1161PubMedCrossRef
17.
go back to reference Thoen J, Helgetveit K, Forre O, Haile Y, Kass E (1988) Effects of piroxicam and D-penicillamine on T lymphocyte subpopulations, natural killer cells and rheumatoid factor production in rheumatoid arthritis. Scand J Rheumatol 17:91–102PubMedCrossRef Thoen J, Helgetveit K, Forre O, Haile Y, Kass E (1988) Effects of piroxicam and D-penicillamine on T lymphocyte subpopulations, natural killer cells and rheumatoid factor production in rheumatoid arthritis. Scand J Rheumatol 17:91–102PubMedCrossRef
18.
go back to reference Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A et al (2004) Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF alpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 63:1218–1221PubMedCrossRef Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A et al (2004) Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF alpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 63:1218–1221PubMedCrossRef
19.
go back to reference Chen HA, Lin KC, Chen CH, Liao HT, Wang HP, Chang HN et al (2006) The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 65:35–39PubMedCrossRef Chen HA, Lin KC, Chen CH, Liao HT, Wang HP, Chang HN et al (2006) The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 65:35–39PubMedCrossRef
20.
go back to reference Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G (2006) Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 65:453–458PubMedCrossRef Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G (2006) Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 65:453–458PubMedCrossRef
22.
go back to reference Sokka T, Hetland ML, Mäkinen H, Kautiainen H, Hørslev-Petersen K, Luukkainen RK et al (2008) Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. Arthritis Rheum 58:2642–2651PubMedCrossRef Sokka T, Hetland ML, Mäkinen H, Kautiainen H, Hørslev-Petersen K, Luukkainen RK et al (2008) Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. Arthritis Rheum 58:2642–2651PubMedCrossRef
23.
go back to reference Mäkinen H, Hannonen P, Sokka T (2006) Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomised clinical trials for the rate of remission. Clin Exp Rheumatol 24(Suppl 43):S22–S28 Mäkinen H, Hannonen P, Sokka T (2006) Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomised clinical trials for the rate of remission. Clin Exp Rheumatol 24(Suppl 43):S22–S28
Metadata
Title
Relation of rheumatoid factor and anti-cyclic citrullinated peptide antibody with disease activity in rheumatoid arthritis: cross-sectional study
Authors
Jung-Yoon Choe
Jisuk Bae
Hwajeong Lee
Sang-Cheol Bae
Seong-Kyu Kim
Publication date
01-09-2013
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 9/2013
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-013-2734-z

Other articles of this Issue 9/2013

Rheumatology International 9/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine